← feed

Is NCT03187496 results overdue?

Yes — results are overdue. Primary completion was 2017-06-01; the FDAAA-801 reporting deadline (2018-06-01) passed 2942 days ago and no results are posted on ClinicalTrials.gov.

Drug-drug Interaction Study Between EDP-305, Midazolam, Caffeine and Rosuvastatin in Healthy Volunteers.

NCT IDNCT03187496 ↗
SponsorEnanta Pharmaceuticals, Inc (INDUSTRY)
Public issuerENANTA PHARMACEUTICALS INC — ENTA (CIK 0001177648) best-effort name match, 95% conf — verify on EDGAR ↗
PhasePHASE1
StatusCOMPLETED
Primary completion2017-06-01 (ACTUAL)
Reporting deadline2018-06-01 (completion + 365d)
Days overdue2942
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 a548fcaacf97ea22… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT03187496. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →